Navigation Links
Misonix Schedules First Quarter Fiscal 2012 Financial Results Conference Call; November 9, 2011 at 4:30 p.m. Eastern
Date:11/8/2011

FARMINGDALE, N.Y., Nov. 8, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative therapeutic ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, today announced plans to release first quarter ended September 30, 2011 financial results on Wednesday, November 9, 2011.  Michael A. McManus, President and Chief Executive Officer and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call at 4:30 p.m. Eastern on Wednesday, November 9, 2011 to discuss the Company's first quarter 2012 financial results.

Shareholders and other interested parties may participate in the conference call by dialing 866 783 2138 (domestic) or 857 350 1597 (international) and entering access code 31240745, a few minutes before the start of the call.  A simultaneous webcast will be available via Misonix's website at www.misonix.com.  The call will be archived on the Company's website for at least 90 days.

A recording of the live-call will be available approximately 2 hours after the event through November 16, 2011.  The dial-in number to listen to the recording is 888 286 8010 or 617 801 6888.  The replay access code is 74394535.

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Investor Relations Contact:
Kevin M. McGrath
Cameron Associates, Inc.
212 245 4577
Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Announces its Exhibition at the European Association of Neurosurgical Societies
2. Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care
3. Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques
4. Misonix Announces New Distribution Agreement for Austria, Germany & Switzerland
5. Misonix Announces the Sale of Its Laboratory and Forensic Safety Products Business for $1.5 Million
6. Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results
7. Misonix Schedules Fourth Quarter and Year-End Fiscal 2011 Financial Results Conference Call; September 20, 2011 at 4:30 p.m. Eastern
8. Misonix Announces New Distribution Agreement for Australia and New Zealand
9. Misonix Announces Entry Into Surgical Wound Debridement
10. Misonix Announces Update of Product Registration in Brazil
11. Misonix Announces New Distribution Agreement for Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology:
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Offering the ... with an oil many times purer and more potent than the market has seen ... of Gstaad, Switzerland, as well as a patented chromatography process for extraction, to produce ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... in hospitals, today announced it has completed a round of funding to accelerate ... and its partners. Black Granite Capital is a growth equity firm focused on ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the ATA 2017 President’s Awards recipients, comprised of organizations and individuals who ... , The ATA 2017 President’s Awards recognize individuals and organizations on ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president and CEO ... Enterprising Women magazine as one of its 2017 Enterprising Women of the Year, ... have demonstrated that they have fast-growth businesses, mentor or actively support other women ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Miami native ... as a dentist. , “I could have never imagined back in 1991 that this ... said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant ...
Breaking Medicine News(10 mins):